Wayne Hellstrom, MD
Urology · New Orleans, LANPI 1689767980
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and grants — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Gilead at 38.5% of the total. Reporting peaked in 2020 at $66,522 and has fallen 80.0% since, to $13,284 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $617.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$71K
- Endo Pharmaceuticals Inc.$54K
- Boston Scientific$24K
- Endo USA, Inc.$12K
- Jazz Pharmaceuticals Inc.$8K
- Coloplast$7K
- plus $7K from 13 others
Across 2 payments — averaging $14,844 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo Pharmaceuticals Inc.$30K
What the payments were for
- Consulting fees$107,21058%
- Speaking & faculty fees$28,46516%
- Grants$20,00011%
- Travel & lodging$11,5806%
- Food & beverage$15,4908%
- Education$5810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 11 | $70,632 |
| Endo Pharmaceuticals Inc. | 87 | $53,804 |
| Boston Scientific | 61 | $24,349 |
| Endo USA, Inc. | 13 | $11,934 |
| Jazz Pharmaceuticals Inc. | 6 | $8,000 |
| Coloplast | 79 | $7,192 |
| Acerus Pharmaceuticals Corporation | 4 | $3,266 |
| Antares Pharma, Inc. | 17 | $2,621 |
| Clarus Therapeutics Inc. | 2 | $396 |
| Astellas Pharma US Inc | 5 | $355 |
| Procept Biorobotics Corporation | 1 | $166 |
| Teleflex LLC | 2 | $160 |
| Cook Medical LLC | 2 | $135 |
| Bard Access Systems, Inc. | 1 | $120 |
| KARL Storz Endoscopy-america | 1 | $65 |
| Urogen Pharma, Inc. | 2 | $63 |
| Merck | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$63,526
- GENERAL MALE SUI$10,000
- GENERAL ERECTILE DYSFUNCTION$10,000
- JZP-150$7,000
- TITAN$6,063
- Natesto$3,206
- TLANDO$2,123
- JATENZO$1,125
- AMS 700 CXR RTE KIT$1,005
- AMS 700$816
- AMS$563
- AQUABEAM SYSTEM$166
- ADVANCE$144
- XYOSTED$130
- CYTUITY$125
- SKYLITE$120
- AMS AMBICOR$115
- LITHO 150$113
- XTANDI$112
How this compares
$183,325 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyostedTestosterone Enanthate | 11 | $6,768 |
| MyrbetriqMirabegron | 13 | $6,693 |
| Testosterone Cypionate | 40 | $1,736 |
| Trospium Chloride | 17 | $980 |
| Tamsulosin Hcl | 55 | $603 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $568 |
| Finasteride | 25 | $270 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $86 |
| Levofloxacin | 22 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Antares Pharma, Inc.Xyosted | $2,621 | $6,76811 claims |
| Astellas Pharma US IncMyrbetriq | $355 | $6,69313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.